Deals
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
FEATURED STORIES
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
While merger and acquisition activity has been robust of late, frequent changes in guidance and leadership at the regulator add risk to any transaction.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
The Boston-based company merged with Capstar Special Purpose Acquisition Corp. and will begin trading on the New York Stock Exchange under the ticker symbol “GLS.”
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
With billions of dollars at stake in potential legal liabilities, the life sciences giant is exploring a possible solution – bankruptcy of a sort.
Medtech company HeartFlow is heading to the New York Stock Exchange through a merger with special purpose acquisition company, Longview Acquisition Corp. II.
Prenetics, which is a diagnostics and genetics testing company, will merge with Artisan Acquisition, a SPAC company backed by Adrian Cheng, chief executive officer of Hong Kong’s New World Development.
No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.
Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
